Kit for testing 3-sulfate glycochenodeoxycholic acids and glycochenodeoxycholic acids in blood

A technology of glycochenodeoxycholic acid sulfate and glycochenodeoxycholic acid, which is applied in the field of analytical chemistry and medicine, can solve the problems of undetectable monosulfated bile acids, cumbersome pretreatment process, and large ion suppression effect. Achieve the effects of improving separation and resolution capabilities, enhancing detection accuracy, and simplifying the pretreatment process

Inactive Publication Date: 2011-03-30
DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI +1
View PDF3 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But these techniques can only detect 15 bile acids that are routinely found in the human body, and cannot detect any monosulfated bile acids
However, there are few methods for detecting monosulfated bile acids, and the pretreatment process is cumbersome. Multi-step SPE columns are used to separate sulfurized bile acids, which has a large ion suppression effect and low resolution, so it can only be used to detect monosulfated bile acids. Disadvantages such as bile acids (see references: Ikegawa S, Yanagihara T, Murao N, etc. JOURNALOF MASS SPECTROMETRY.1997, 32, 401-407.)
Currently, there is no rapid and efficient method for detecting both regular and sulfated bile acids in humans, and no one has correlated changes in individual bile acids with primary liver cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for testing 3-sulfate glycochenodeoxycholic acids and glycochenodeoxycholic acids in blood
  • Kit for testing 3-sulfate glycochenodeoxycholic acids and glycochenodeoxycholic acids in blood
  • Kit for testing 3-sulfate glycochenodeoxycholic acids and glycochenodeoxycholic acids in blood

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] 1. Serum Sample Collection

[0026] Before the collection, the included volunteers signed the informed consent form.

[0027] Normal control, hepatitis, liver cirrhosis and primary liver cancer group inclusion criteria: refer to "Huang Jiasi Surgery (7th Edition)" People's Medical Publishing House, 2008 Beijing

[0028] Under the same conditions, 36 cases of normal people, 14 cases of confirmed hepatitis, 15 cases of liver cirrhosis and 45 cases of liver cancer were collected. After collection, they were left at 4°C for half an hour, centrifuged at 9000g for 15 minutes, and the supernatant was stored immediately. Store in a -80°C refrigerator for later use.

[0029] 2. Analysis method

[0030] 2.1 Serum sample pretreatment

[0031] When the sample is to be tested, thaw at room temperature, take 150 μl of serum, add 600 μl of acetonitrile, 30 μl of isoleucine oriferin, the concentration of which is 3.3 μg / ml of acetonitrile aqueous solution (the volume ratio of aceton...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a kit for testing 3-sulfate glycochenodeoxycholic acids and glycochenodeoxycholic acids in blood, which consists of internal standard isoleucine peptides, buffer solution ammonium acetates and acetonitrile. A method for testing the 3-sulfate glycochenodeoxycholic acids and glycochenodeoxycholic acids in blood by using the kit has the characteristics of low testing cost, good repeatability, high stability, speediness, and high efficiency; and a test on an actual sample by the kit only takes19 minutes, therefore, the kit is suitable for clinical application.

Description

technical field [0001] The invention relates to the fields of analytical chemistry and medicine, and is a kit for detecting 3-sulfate glycochenodeoxycholic acid and glycochenodeoxycholic acid (GCDCS and GCDCA) in blood, and performs ultra-high performance liquid chromatography mass spectrometry on human blood Combined with high-temperature and high-speed analysis, it is a technology for rapid quantitative determination of GCDCS and GCDCA in blood. Background technique [0002] Liver cancer is one of the common malignant tumors in my country. Liver cancer either begins in the liver itself, or arises from the metastatic action of other cancer cells in the body. Primary liver cancer refers to malignant tumors that occur in liver cells or intrahepatic cholangiocytes. The incidence of primary liver cancer that starts in the liver has always been the first among liver malignant tumors. It is second only to gastric cancer and esophageal cancer in the mortality rate of malignant t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N30/02G01N30/72
CPCG01N2030/8813G01N30/7233G01N33/94
Inventor 王文昭谈冶雄尹佩源洪毅路鑫汤靓王红阳许国旺
Owner DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap